for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Humanwell Healthcare Group Co Ltd

600079.SS

Latest Trade

12.02CNY

Change

0.10(+0.84%)

Volume

8,103,097

Today's Range

11.90

 - 

12.07

52 Week Range

8.35

 - 

14.15

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
11.92
Open
11.97
Volume
8,103,097
3M AVG Volume
199.07
Today's High
12.07
Today's Low
11.90
52 Week High
14.15
52 Week Low
8.35
Shares Out (MIL)
1,353.70
Market Cap (MIL)
16,136.16
Forward P/E
18.80
Dividend (Yield %)
--

Latest Developments

More

Humanwell Healthcare's H1 Net Profit Down 32.9% Y/Y

Humanwell Healthcare Swings To Net Loss Of 2.36 Bln Yuan In 2019

BRIEF-Humanwell Healthcare Expects to Swing To Net Loss In 2018

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Humanwell Healthcare Group Co Ltd

Humanwell Healthcare (Group) Co., Ltd is a China-based company principally engaged in research and development, manufacture and distribution of medical and pharmaceutical products. The Company’s products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and others. The Company also provides medical instruments. The Company distributes its products in both domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 666

Gaoxin Avenue

Donghu High-Tech Development District

+86.27.87597232

http://www.humanwell.com.cn

Executive Leadership

Xue Hai Wang

Chairman of the Board

Jie Li

President, Director

Yajun Wu

Chief Financial Officer, Vice President

Qianlun Li

Vice President, Secretary of the Board

Xia Fei Deng

Vice President, Director

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

12.3K

2017

15.4K

2018

18.6K

2019(E)

22.3K
EPS (CNY)

2016

0.630

2017

1.528

2018

0.665

2019(E)

0.634
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.79
Price To Book (MRQ)
1.42
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
152.12
LT Debt To Equity (MRQ)
39.46
Return on Investment (TTM)
-11.82
Return on Equity (TTM)
-5.62

Latest News

REFILE-BRIEF-Humanwell Healthcare Expects to Swing To Net Loss In 2018

* SAYS IT SEES 2018 NET LOSS OF 2.2-2.7 BILLION YUAN VERSUS NET PROFIT OF 2.1 BILLION YUAN ($311.81 million) YEAR EARLIER

BRIEF-Humanwell Healthcare Expects 2017 Net Profit To Rise 108-114 Percent Y/Y

* SAYS IT EXPECTS 2017 NET PROFIT TO RISE 108-114 PERCENT Y/Y VERSUS 832 MILLION YUAN ($131.56 million) YEAR AGO Source text in Chinese: http://bit.ly/2DIIsBj Further company coverage: ($1 = 6.3242 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Humanwell Healthcare Group sells bio-pharma firm for 350 mln yuan

* Says it sold 100 percent stake in Yichang-based bio-pharma firm for 350 million yuan

BRIEF-Humanwell Healthcare's Unit To Boost Capital Of Lifestyles Healthcare

* SAYS UNIT SIGNS AGREEMENT TO BOOST CAPITAL OF LIFESTYLES HEALTHCARE PTE WITH HEALTH PRODUCTS FIRM'S 59 PERCENT STAKE WORTH $131.1 MILLION Source text in Chinese: http://bit.ly/2kK6weL Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Humanwell Healthcare Group completes investment in unit RFSW Investment Pte Ltd

* Says it invested 805.4 million yuan in wholly owned Singapore unit RFSW Investment Pte. Ltd

BRIEF-Humanwell Healthcare Group unit gets approval of clinical trial for Meisuoshuli tablets

* Says its Wuhan-based unit gets approval of clinical trial for Meisuoshuli tablets, which is used for anti-inflammatory, analgesic and antipyretic

BRIEF-Humanwell Healthcare's shareholder bought shares worth 143.7 mln yuan during Jun 28-Nov 29

* SAYS CONTROLLING SHAREHOLDER HAS BOUGHT 143.7 MILLION YUAN ($21.78 million) WORTH OF COMPANY SHARES BETWEEN JUNE 28 AND NOV 29 Source text in Chinese: http://bit.ly/2k9Y2AT Further company coverage: ($1 = 6.5966 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Humanwell Healthcare Group unit passes FDA approval

* Says its 75 percent-owned unit received approval for its soft capsule named Dutasteride Capsule from U.S Food and Drug Administration

BRIEF-Humanwell Healthcare Group receives subsidy

* Says it received subsidy of 35 million yuan from government, on Nov. 15

BRIEF-Humanwell Healthcare and unit to increase stake in Tianfeng Securities

* Says it and unit plan to acquire additional 2.18 percent stake in Tianfeng Securities for 305.1 million yuan ($45.97 million)

BRIEF-Humanwell Healthcare's 9-month net profit up 211.3 pct y/y

Humanwell Healthcare Group Co Ltd * Says 9-month net profit up 211.3 percent y/y Source text in Chinese: http://bit.ly/2gV5KgU Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Humanwell Healthcare Group unit receives approval for drug clinical trial

* Says unit Yichang Humanwell pharmaceutical Co Ltd received approval for drug clinical trial for a kind of injection M6G, from China Food and Drug Administration

BRIEF-Humanwell Healthcare to invest 805.4 mln yuan in unit RFSW Investment Pte Ltd

* Says it signs agreement to invest 805.4 million yuan ($121.45 million) in unit RFSW Investment Pte. Ltd

BRIEF-Humanwell Healthcare Group unit receives FDA approval

* Says its unit, PuraCap Pharmaceutical LLC, received approval for its Pioglitazone Tablet from U.S Food and Drug Administration

BRIEF-Humanwell Healthcare Group jointly acquires sexual health business of Ansell Ltd with CITIC Capital Cupid Investment

* Says it acquired Wuhan-based sanitation supplies unit of Ansell Ltd. for $120 million

BRIEF- Humanwell Healthcare Group unit sets up U.S. joint stock company for asset acquisition

* Says its unit Humanwell Healthcare USA,LLC set up U.S. joint stock company AGIC-HUMANWELL BLUE RIDGE (US) LIMITED

BRIEF-Humanwell Healthcare Group unit receives GMP certificate

* Says its pharma unit received goods manufacture practice (GMP) certificate from Hubei Food and Drug Administration on Jan. 2

BRIEF-Humanwell Healthcare Group issues 2017 1st tranche short-term financing notes worth 1 bln yuan

* Says it completed issuance of 2017 1st tranche short-term financing notes worth 1 billion yuan

REFILE-BRIEF-Humanwell Healthcare to issue medium-term notes, sell bio-pharma unit

* Says it plans to issue up to 2.0 billion yuan ($303.19 million) medium-term notes

BRIEF-Humanwell Healthcare Group issues 2017 3rd tranche super short-term financing notes worth 1.2 bln yuan

* Says it issued 2017 3rd tranche super short-term financing notes worth 1.2 billion yuan with a term of 270 days and interest rate of 4.6 percent

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up